Last reviewed · How we verify
BioRay Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
1 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Perjeta | Perjeta | marketed | Receptor tyrosine-protein kinase erbB-2 | Oncology | ||
| HS627 | HS627 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes |
Therapeutic area mix
- Oncology · 2
- Diabetes · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Beijing Tiantan Hospital · 2 shared drug classes
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 2 shared drug classes
- Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
- Asan Medical Center · 2 shared drug classes
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · 2 shared drug classes
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 2 shared drug classes
- Addpharma Inc. · 2 shared drug classes
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for BioRay Pharmaceutical Co., Ltd.:
- BioRay Pharmaceutical Co., Ltd. pipeline updates — RSS
- BioRay Pharmaceutical Co., Ltd. pipeline updates — Atom
- BioRay Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). BioRay Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioray-pharmaceutical-co-ltd. Accessed 2026-06-10.